The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma

INTRODUCTION: Immune checkpoint inhibition (ICI) plus bevacizumab (BEV) is the standard first-line treatment for unresectable hepatocellular carcinoma (uHCC). We aimed to assess the efficacy and safety of ICI plus bevacizumab and ICI plus receptor tyrosine kinase inhibitor (TKI) in this patient popu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Hui, Xu, Qi, Wang, Jinyu, Xu, Xiaoqing, Luo, Jun, Zhang, Lei, Luo, Cong, Ying, Jieer, Li, Jingjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900113/
https://www.ncbi.nlm.nih.gov/pubmed/36756114
http://dx.doi.org/10.3389/fimmu.2023.1073133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900113/
https://www.ncbi.nlm.nih.gov/pubmed/36756114
http://dx.doi.org/10.3389/fimmu.2023.1073133

Ejemplares similares